Using a Revenue DCF model with operating margin convergence from -2091.2% to a target of 13.2% over 5 years, discounted at a WACC of 10.9%, Mainz Biomed N.V. (QUCY) has an intrinsic value of $237.94 per share (range: $131.54 – $427.46).
Using the industry peer median EV/Revenue multiple (trailing + forward), Mainz Biomed N.V. (QUCY) has a fair value of $7.71 based on 10 comparable companies in the Medical - Diagnostics & Research industry.
USD in millions except Fair Price. Subject company highlighted.
| Mkt Cap ($M) | Trailing EV/Revenue | Forward EV/Revenue | |
|---|---|---|---|
| Mainz Biomed N.V.QUCY | 0 | -2.9x | -3.0x |
| Thermo Fisher Scientific Inc. | 176,319 | 4.7x | 4.4x |
| Danaher Corporation | 121,142 | 5.5x | 5.3x |
| IDEXX Laboratories, Inc. | 44,183 | 10.5x | 9.6x |
| Agilent Technologies, Inc. | 32,674 | 4.9x | 4.6x |
| IQVIA Holdings Inc. | 29,827 | 2.7x | 2.5x |
| Natera, Inc. | 27,530 | 11.6x | 10.0x |
| Mettler-Toledo International Inc. | 22,855 | 6.2x | 5.9x |
| Labcorp Holdings Inc. | 20,838 | 2.0x | 1.9x |
| Quest Diagnostics Incorporated | 20,743 | 2.5x | 2.5x |
| Exact Sciences Corporation | 20,026 | 6.7x | 5.8x |
| Industry Median | 5.2x | 5.0x | |
| (*) Revenue | 1 | 1 | |
| = Enterprise Value | 5 | 4 | |
| (-) Net Debt | -3 | -3 | |
| Equity Value | 8 | 7 | |
| (/) Outstanding shares | 1 | 1 | |
| Fair Price | $8 | $8 | |
Disclaimer: Sweet Value Lab provides estimated intrinsic values for informational purposes only. This is not financial advice. All models rely on assumptions that may not reflect future performance. Always do your own research before making investment decisions.